These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17134662)

  • 1. The effect of acetaldehyde-glycosaminoglycan mixtures upon Factor IXa and Factor IX-Deficient Plasma.
    Brecher AS; Moon AR; Gray KD
    Alcohol; 2006 Jun; 39(2):97-104. PubMed ID: 17134662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of glycosaminoglycans with acetaldehyde on the activation of prothrombin.
    Brecher AS; Adamu MT
    Can J Physiol Pharmacol; 2005 May; 83(5):431-8. PubMed ID: 15897925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation protein function: enhancement of the anticoagulant effect of acetaldehyde by sulfated glycosaminoglycans.
    Brecher AS; Adamu MT
    Dig Dis Sci; 2001 Sep; 46(9):2033-42. PubMed ID: 11575460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
    Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
    J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of acetaldehyde and glycosaminoglycans upon factor Xa- and factor X-deficient plasma.
    Brecher AS; Hommema EL
    Can J Physiol Pharmacol; 2002 Sep; 80(9):879-86. PubMed ID: 12430983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of glycosaminoglycans on coagulation: a thromboelastographic study.
    Senzolo M; Coppell J; Cholongitas E; Riddell A; Triantos CK; Perry D; Burroughs AK
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):227-36. PubMed ID: 17413758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation protein function: the influence of acetaldehyde-modified heparin on thrombin activity.
    Brecher AS; Fu Q
    J Investig Med; 1999 Jan; 47(1):76-80. PubMed ID: 10071484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate.
    Glauser BF; Pereira MS; Monteiro RQ; Mourão PA
    Thromb Haemost; 2008 Sep; 100(3):420-8. PubMed ID: 18766257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation protein function VI: augmentation of anticoagulant function by acetaldehyde-treated heparin.
    Brecher AS; Hellman K; Basista MH
    Dig Dis Sci; 1999 Jul; 44(7):1349-55. PubMed ID: 10489917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glycosaminoglycans on factor XI activation by thrombin.
    Gailani D; Broze GJ
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):15-20. PubMed ID: 8457645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anticoagulant effect of heparan sulfate and dermatan sulfate.
    Teien AN; Abildgaard U; Höök M
    Thromb Res; 1976 Jun; 8(6):859-67. PubMed ID: 134464
    [No Abstract]   [Full Text] [Related]  

  • 12. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
    Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
    Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microplate coagulation assays.
    Pratt CW; Monroe DM
    Biotechniques; 1992 Sep; 13(3):430-3. PubMed ID: 1389175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA
    Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
    Dol F; Petitou M; Lormeau JC; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B
    J Lab Clin Med; 1990 Jan; 115(1):43-51. PubMed ID: 2299256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
    Fernández JA; Petäjä J; Griffin JH
    Thromb Haemost; 1999 Nov; 82(5):1462-8. PubMed ID: 10595639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.
    Wun TC
    Blood; 1992 Jan; 79(2):430-8. PubMed ID: 1346095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
    Zmuda K; Neofotistos D; Ts'ao CH
    Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.